But since last year, the Indian pharma has specifically being impacted by demonetisation and to some extent GST. Also, in the last three years, there have been additional pricing control and more importantly there was a ban on some stores also which impacted certain companies. Having said that, we ...
Read more: Growth will return to pharma sector in 2018: V Srivatsa of UTI Mutual Fund